Titelia

Holdings of Sands Capital Alternatives, LLC

19 declared positions · as of Mar 31, 2026

Original filing · Ten largest lines: 87.6 % of the equity sleeve

Sector breakdown

  • Consumer discretionary 5.2 %
  • Technology 4.1 %
  • Unattributed 90.7 %

Titelia classification, company by company. The unattributed share stays visible.

Currency breakdown

  • USD 100.0 %

The quoted currency of each line, as declared.

Country breakdown

  • US 100.0 %

Shares computed on the equity sleeve.

RankCountryLinesValueShare
1US19322.6M $100.00 %

Positions

RankCompanySharesValueWeight
1Klaviyo Inc 3,649,67871M $
2SpyGlass Pharma Inc 2,500,01264.8M $
3Beta Bionics Inc 3,708,04337.2M $
4Inhibikase Therapeutics Inc 13,018,96521.9M $
5Coupang Inc 1,012,09119.1M $
6Samsara Inc 560,28717.8M $
7DoorDash Inc 111,23116.7M $
8BioAge Labs Inc 786,35313.8M $
910X Genomics Inc 481,77010.2M $
10Datadog Inc 85,79310.1M $
11Acumen Pharmaceuticals Inc 3,720,1058.8M $
12Toast Inc 301,6478M $
13Tarsus Pharmaceuticals Inc 85,0006M $
14ServiceTitan Inc 89,8565.7M $
15Taysha Gene Therapies Inc 724,8733.2M $
16Snowflake Inc 20,2533.1M $
17Acrivon Therapeutics Inc 2,122,6053M $
18Candel Therapeutics Inc 405,8372M $
19Figma Inc 18,286386.6K $